About Shionogi
About Shionogi
Message from Top Management
Shionogi's Strength
Management Philosophy
Company Profile
Management Strategy
Operations
Compliance
Group Companies
Corporate Governance
Policies
History
TVCM "Medicines and beyond"
Sustainability
Sustainability
Material Issues (Materiality)
Address the problem of antimicrobial resistance (AMR)
Environment
Society
Governance
Access to Healthcare
Stakeholder Engagement
Annual Report / Integrated Report / EHS Report
Data
External Evaluation
About United Nations Global Compact
Information related to infectious diseases
Innovation
Innovation
R&D
Partnering
Pipeline
Wastewater-based Epidemiology Surveillance Service
News
Investors
Contact Us
Careers
Search
English
Worldwide
HOME
News
Shionogi announces positive top-line efficacy results from year-long studies of velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity
Release
2009/02/17
Shionogi announces positive top-line efficacy results from year-long studies of velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity
